Marx Pauline F, Brondijk T Harma C, Plug Tom, Romijn Roland A, Hemrika Wieger, Meijers Joost C M, Huizinga Eric G
Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Blood. 2008 Oct 1;112(7):2803-9. doi: 10.1182/blood-2008-03-146001. Epub 2008 Jun 17.
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-metallocarboxypeptidase that can be proteolytically activated (TAFIa). TAFIa is unique among carboxypeptidases in that it spontaneously inactivates with a short half-life, a property that is crucial for its role in controlling blood clot lysis. We studied the intrinsic instability of TAFIa by solving crystal structures of TAFI, a TAFI inhibitor (GEMSA) complex and a quadruple TAFI mutant (70-fold more stable active enzyme). The crystal structures show that TAFIa stability is directly related to the dynamics of a 55-residue segment (residues 296-350) that includes residues of the active site wall. Dynamics of this flap are markedly reduced by the inhibitor GEMSA, a known stabilizer of TAFIa, and stabilizing mutations. Our data provide the structural basis for a model of TAFI auto-regulation: in zymogen TAFI the dynamic flap is stabilized by interactions with the activation peptide. Release of the activation peptide increases dynamic flap mobility and in time this leads to conformational changes that disrupt the catalytic site and expose a cryptic thrombin-cleavage site present at Arg302. This represents a novel mechanism of enzyme control that enables TAFI to regulate its activity in plasma in the absence of specific inhibitors.
凝血酶激活的纤维蛋白溶解抑制剂(TAFI)是一种前金属羧肽酶,可被蛋白水解激活为TAFIa。TAFIa在羧肽酶中独一无二,因为它会以较短的半衰期自发失活,这一特性对其在控制血凝块溶解中的作用至关重要。我们通过解析TAFI、TAFI抑制剂(GEMSA)复合物以及四重TAFI突变体(活性酶稳定性提高70倍)的晶体结构,研究了TAFIa的内在不稳定性。晶体结构表明,TAFIa的稳定性与一个包含活性位点壁残基的55个残基片段(残基296 - 350)的动力学直接相关。抑制剂GEMSA(一种已知的TAFIa稳定剂)和稳定突变显著降低了该侧翼的动力学。我们的数据为TAFI自我调节模型提供了结构基础:在酶原TAFI中,动态侧翼通过与激活肽的相互作用而稳定。激活肽的释放增加了动态侧翼的流动性,最终导致构象变化,破坏催化位点并暴露出位于精氨酸302处的隐蔽凝血酶切割位点。这代表了一种新的酶控制机制,使TAFI能够在没有特异性抑制剂的情况下调节其在血浆中的活性。